An Evaluation of Neutralizing Antibody Induction During Treatment of Glabellar Lines with a New US Formulation of Botulinum Neurotoxin Type A

Aesthetic Surgery Journal

Volumn 29, Issue 6 SUPPL., 2009, Pages

  Lawrence, Ira ^a   Moy, Ronald ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; NEUTRALIZING ANTIBODY;

ADULT; AGED; ARTICLE; ASTHENOPIA; BIOASSAY; BLOOD SAMPLING; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FEMALE; FOLLOW UP; GLABELLAR LINE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PTOSIS; RADIOIMMUNOPRECIPITATION; TREATMENT DURATION; TREATMENT RESPONSE; UNITED STATES; WRINKLE;

AGED; ANTIBODIES, NEUTRALIZING; BOTULINUM TOXIN TYPE A; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROTOXINS; RADIOIMMUNOASSAY; SENSITIVITY AND SPECIFICITY; SKIN AGING; TREATMENT OUTCOME;

EID: 71549173397     PISSN: 1090820X     EISSN: 1527330X     Source Type: Journal    
DOI: 10.1016/j.asj.2009.09.009     Document Type: Article

References (22)

1. American Society for Aesthetic Plastic Surgery website. Cosmetic Surgery National Data Bank statistics 2008. (Accessed August 29, 2009, at http://www.surgery.org/sites/default/files/2008stats.pdf)
2. Göschel H., Wohlfarth K., Frevert J., Dengler R., and Bigalke H. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies-therapeutic consequences. Exp Neurol 147 (1997) 96-102
3. Jankovic J., Vuong K.D., and Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 60 (2003) 1186-1188
4. Aoki K.R. Pharmacology and immunology of botulinum neurotoxins. Int Ophthalmol Clin 45 (2005) 25-37
5. Atassi M.Z. Basic immunological aspects of botulinum toxin therapy. Mov Disord 19 suppl 8 (2004) S68-S84
6. Borodic G. Botulinum toxin, immunologic considerations with long-term repeated use, with an emphasis on cosmetic applications. Facial Plast Surg Clin North Am 15 (2007) 11-16
7. Borodic G., Johnson E., Goodnough M., and Schantz E. Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology 46 (1996) 26-29
8. Brin M.F., Comella C.L., Jankovic J., Lai F., Naumann M., and CD-017 BoNTA Study Group. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord 23 (2008) 1353-1360
9. Borodic G. Immunologic resistance after repeated botulinum toxin type A injections for facial rhytides [letter]. Ophthal Plast Reconstr Surg 22 (2006) 239-240
10. Jankovic J., and Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology 45 (1995) 1743-1746
11. Hanna P.A., Jankovic J., and Vincent A. Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies. J Neurol Neurosurg Psychiatry 66 (1999) 612-616
12. Moy R., Maas C., Monheit G., Huber B., and Reloxin Investigational Group. Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines. Arch Facial Plast Surg 11 (2009) 77-83
13. Brandt F., Swanson N., Baumann L., and Huber B. Randomized, placebo-controlled study of a new botulinum toxin type A for treatment of glabellar lines: efficacy and safety. Dermatol Surg (2009 June 22) [Epub ahead of print].
14. Monheit G.D., Cohen J.L., and Reloxin Investigational Group. Long-term safety of repeated administrations of a new formulation of botulinum toxin type A in the treatment of glabellar lines: interim analysis from an open-label extension study. J Am Acad Dermatol 61 (2009) 421-425
15. Morte C, Pla F, Cedo M, et al. Development of a multi-step approach for the detection of neutralizing antibodies to botulinum toxin type A. Presented at Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins. Baveno, Italy, June 12-15, 2008.
16. Rosenberg J.S., Middlebrook J.L., and Atassi M.Z. Localization of the regions on the C-terminal domain of the heavy chain of botulinum A recognized by T lymphocytes and by antibodies after immunization of mice with pentavalent toxoid. Immunol Invest 26 (1997) 491-504
17. Oshima M., Hayakari M., Middlebrook J.L., and Atassi M.Z. Immune recognition of botulinum neurotoxin type A: regions recognized by T cells and antibodies against the protective H(C) fragment (residues 855-1296) of the toxin. Mol Immunol 34 (1997) 1031-1040
18. Ascher B., Zakine B., Kestemont P., Baspeyras M., Bougara A., and Santini J. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol 51 (2004) 223-233
19. Agresti A., and Caffo B. Simple and effective confidence intervals for proportions and differences of proportions result from adding two successes and two failures. Am Stat 54 (2000) 280-288
20. Rubin M.G., Dover J.S., Glogau R.G., Goldberg D.J., Goldman M.P., and Schlessinger J. The efficacy and safety of a new US botulinum toxin type A in the retreatment of glabellar lines following open-label treatment. J Drugs Dermatol 8 (2009) 439-444
21. Kane M.A., Brandt F., Rohrich R.J., Narins R.S., Monheit G.D., and Huber M.B. Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase 3, randomized, double-blind, placebo-controlled study. Plast Reconstr Surg (2009 Jul 28) [Epub ahead of print].
22. Dressler D., and Hallett M. Immunological aspects of Botox, Dysport, and Myobloc/NeuroBloc. Eur J Neurol 13 suppl 1 (2006) 11-15